GGrantIndex
← Leaderboards

Ruth B. Caldwell

Augusta University

$11,181,117
Attributed
$17,411,128
Total exposure
12
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.8M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$17,411,128 · 9
VA$0 · 3

By mechanism

R01$16,409,947 · 6
R24$444,150 · 1
R21$417,725 · 1
R43$139,306 · 1
I01$0 · 2
IK6$0 · 1

Top collaborators

Most similar at Augusta University

Same institution · by research overlap

Others in their field

Top investigators on “Retina

Research focus

RetinaMolecularBlood VesselsRetinal DiseasesEndothelial CellsVascular Endothelial Growth FactorsCellsEnzymesProductionDiabetic RetinopathyOxygenMediatingPreventIn VitroNitric Oxide SynthaseBlindnessPathway InteractionsMacrophageIn VivoInflammatoryDesignInjuryProtein IsoformsNovel Strategies

Grant awards (60)

Adenosine receptor 2A in subretinal fibrosis$402,276
R01 · FY2025 · EY
"Myeloid PFKFB3 in subretinal fibrosis"$400,332
R01 · FY2025 · EY · contact PI
Myeloid ACAT1 in ischemic retinopathy$385,000
R01 · FY2025 · EY · contact PI
Adenosine receptor 2A in subretinal fibrosis$437,751
R01 · FY2024 · EY
"Myeloid PFKFB3 in subretinal fibrosis"$400,332
R01 · FY2024 · EY · contact PI
Myeloid ACAT1 in ischemic retinopathy$385,000
R01 · FY2024 · EY · contact PI
Myeloid glycolysis in pathological ocular angiogenesis$452,760
R01 · FY2023 · EY · contact PI
Adenosine receptor 2A in subretinal fibrosis$437,751
R01 · FY2023 · EY
"Myeloid PFKFB3 in subretinal fibrosis"$400,332
R01 · FY2023 · EY · contact PI
Myeloid glycolysis in pathological ocular angiogenesis$439,177
R01 · FY2022 · EY · contact PI
Adenosine receptor 2A in subretinal fibrosis$437,751
R01 · FY2022 · EY
"Myeloid PFKFB3 in subretinal fibrosis"$400,332
R01 · FY2022 · EY · contact PI
Myeloid glycolysis in pathological ocular angiogenesis$355,411
R01 · FY2022 · EY · contact PI
Role of ACAT1 in Pathological Retinal Neovascularization$186,725
R21 · FY2022 · EY · contact PI
Myeloid glycolysis in pathological ocular angiogenesis$439,177
R01 · FY2021 · EY · contact PI
Cellular Mechanisms of Retinopathy: Role of Arginase$373,450
R01 · FY2021 · EY · contact PI
Role of ACAT1 in Pathological Retinal Neovascularization$231,000
R21 · FY2021 · EY · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2021 · VA · contact PI
Myeloid glycolysis in pathological ocular angiogenesis$452,760
R01 · FY2020 · EY · contact PI
Cellular Mechanisms of Retinopathy: Role of Arginase$385,000
R01 · FY2020 · EY · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2020 · VA · contact PI
Myeloid glycolysis in pathological ocular angiogenesis$448,718
R01 · FY2019 · EY · contact PI
Cellular Mechanisms of Retinopathy: Role of Arginase$381,563
R01 · FY2019 · EY · contact PI
Mechanisms of Traumatic Retinal Injury: Targeting the Arginase Pathway$0
I01 · FY2019 · VA · contact PI
Cellular Mechanisms of Retinopathy: Role of Arginase$381,250
R01 · FY2018 · EY · contact PI
Mechanisms of Traumatic Retinal Injury: Targeting the Arginase Pathway$0
I01 · FY2018 · VA · contact PI
Cellular Mechanisms of Retinopathy: Role of Arginase$414,785
R01 · FY2017 · EY · contact PI
Mechanisms of Traumatic Retinal Injury: Targeting the Arginase Pathway$0
I01 · FY2017 · VA · contact PI
Cellular Mechanisms of Retinopathy: Role of Arginase$414,785
R01 · FY2016 · EY · contact PI
Mechanisms of Traumatic Retinal Injury: Targeting the Arginase Pathway$0
I01 · FY2016 · VA · contact PI
Cellular Mechanisms of Retinopathy: Role of Arginase$406,489
R01 · FY2015 · EY · contact PI
Mechanisms of Diabetic Retinopathy: Oxidative Stress and Inflammation$0
I01 · FY2015 · VA · contact PI
Cellular Mechanisms of Retinopathy: Role of Arginase$406,490
R01 · FY2014 · EY · contact PI
Mechanisms of Diabetic Retinopathy: Oxidative Stress and Inflammation$0
I01 · FY2014 · VA · contact PI
Cellular Mechanisms of Retinopathy: Role of Arginase$414,785
R01 · FY2013 · EY · contact PI
Mechanisms of Diabetic Retinopathy: Oxidative Stress and Inflammation$0
I01 · FY2013 · VA · contact PI
Novel Strategies for prevention of diabetic vascular dysfunction.$444,150
R24 · FY2012 · DK
Mechanisms of Diabetic Retinopathy: Oxidative Stress and Inflammation$0
I01 · FY2012 · VA · contact PI
Cellular Mechanisms of Retinal Angiogenesis$349,272
R01 · FY2011 · EY · contact PI
Cellular Mechanisms of Retinal Angiogenesis$363,825
R01 · FY2010 · EY · contact PI
Blood-Retinal Barrier Changes in Retinopathy$353,275
R01 · FY2010 · EY · contact PI
Cellular Mechanisms of Retinal Angiogenesis$365,103
R01 · FY2009 · EY · contact PI
Blood-Retinal Barrier Changes in Retinopathy$356,843
R01 · FY2009 · EY · contact PI
Blood-Retinal Barrier Changes in Retinopathy$349,706
R01 · FY2008 · EY · contact PI
Blood-Retinal Barrier Changes in Retinopathy$356,235
R01 · FY2007 · EY · contact PI
Cellular Mechanisms of Retinal Angiogenesis$277,715
R01 · FY2007 · EY · contact PI
Blood-Retinal Barrier Changes in Retinopathy$346,600
R01 · FY2006 · EY · contact PI
Cellular Mechanisms of Retinal Angiogenesis$279,279
R01 · FY2006 · EY · contact PI
Cellular Mechanisms of Retinal Angiogenesis$286,000
R01 · FY2005 · EY
Cellular Mechanisms of Retinal Angiogenesis$286,000
R01 · FY2004 · EY
Blood-retinal Barrier Changes in Retinopathy$251,125
R01 · FY2004 · EY
Cellular Mechanisms of Retinal Angiogenesis$275,250
R01 · FY2003 · EY
Blood-retinal Barrier Changes in Retinopathy$251,125
R01 · FY2003 · EY
Improved actions of nitrates and statins with L-arginine$139,306
R43 · FY2003 · HL
Blood-retinal Barrier Changes in Retinopathy$251,125
R01 · FY2002 · EY
CELLULAR MECHANISMS OF RETINAL ANGIOGENESIS$225,050
R01 · FY2002 · EY
Blood-retinal Barrier Changes in Retinopathy$250,048
R01 · FY2001 · EY
CELLULAR MECHANISMS OF RETINAL ANGIOGENESIS$233,238
R01 · FY2001 · EY
CELLULAR MECHANISMS OF RETINAL ANGIOGENESIS$227,014
R01 · FY2000 · EY
BLOOD/RETINAL BARRIER CHANGES IN RETINOPATHY$222,662
R01 · FY2000 · EY